Baxter International Inc.

Baxalta Gmbh

Other

Baxter Healthcare Sa

Edwards Lifesciences Corporation

Baxter Travenol Laboratories, Inc.

Innate Biotech, Inc.

Richard J Johnson

Neng S Ung-Chhun

Hans-Peter Schwarz

Dean G Laurin

Wolfgang Teschner

Ruth Madlener

Shawn F Bairstow

Sindhu Ramachandran

Daniel R Boggs

Crystal M Cunanan

Michael J Lysaght

Cecilia S Ku

Dennis E Chenoweth

Julian P Breillatt, Jr

Julian Breillatt

Clifford J Holmes

Run Wang

Valerie Leesch

Shelley A Maves

Zheng Jenny Zhang

Crystal M Cunahan

The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H.

Factor H for treatment of rheumatoid arthritis

Factor H for transplantation

The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.

Manufacture of factor H (FH) and FH-derivatives from plasma

Methods of treating a dialysis component by providing a dialysis component and contacting the dialysis component with an enzyme are provided. The enzyme breaks down microbial contaminants in the dialysis component. The enzyme may be separated from the dialysis component to provide a purified dialysis component. The purified dialysis component may be substantially free of microbial contaminants that cause a cytokine response in humans.

Destruction of microbial products by enzymatic digestion

Medical devices and methods of producing same are provided. The medical device comprising a body member and a coating on at least a portion of the body member comprising an insitu condensation product of a first electrophilically active, high molecular weight polyalkylene oxide and a second high molecular weight polyoxyalkylene derivative.

Medical devices and products having coatings applied thereto

The present invention relates to compositions, including pharmaceutical compositions that inhibit complement activation, and contain amino acid sequences X-X-X-W-E-X-X-Xand/or Z-C-Z-P-Z-Z-C-Zas described. The invention further relates to methods of inhibiting complement activation in vivo or ex vivo by administering a pharmaceutical composition as described herein.

Peptides that inhibit complement activation

Method for producing improved medical devices and devices so produced

A cleanup kit designed to be used by a person walking a dog to enable him to remove any litter deposited by the animal and then to flush and sanitize the spot contaminated by the litter. The kit includes a bag and shoulder carrying strap. The bag includes multiple internal compartments for supporting the kit items which include a trigger sprayer, a flashlight, cleanup gloves, disposable litter bags, and a variety of other optional items. A bag insert is designed to convert a conventional bag to one having compartments to retain the kit items.

Dog litter clean up kit and method

Novel blood cell fractionation devices are provided. The device utilizes filters coated with high molecular weight polyethylene oxide derivatives cross-linked to prevent leaching from filter surfaces. These filters have a special efficacy in preventing protein adsorption and cellular adhesion to the membrane filter.

Method of filtering a fluid suspension with a membrane having a

A tyrosine-substituted hirudin analog has antithrombogenic activity. Further simultaneous reaction at native tyrosine residues is prevented by mutation at those sites to encode nonreactive amino acids. Several novel strategies for coupling the hirudin analog to solid surfaces while simultaneously conserving antithrombogenic activity are disclosed.

Analogs of hirudin

Blood filtration devices and methods of filtering are disclosed. In part, a blood filtration device is provided comprising a housing defining an interior periphery. The device includes a rotating structure mounted within the interior periphery and defining with the housing an annular gap within the interior periphery, an inlet fluid path for allowing a blood product to flow into the annular gap, and the rotating structure including an exterior surface that includes a filter membrane. The filter membrane has a coating thereon comprising an insitu condensation product of a first electrophilically active, high molecular weight polyalkylene oxide and a second high molecular weight bifunctional diamino-polyoxyalkylene oxide derivative.

Blood cell separation devices having a membrane with particular coating

Growing community of inventors

Mundeline, IL, United States of America

Richard J Johnson